Immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD‐1)/programmed cell death protein ligand 1 (PD‐L1) blockade therapy [132], have been demonstrated to be valuable in the treatment of patients with non-small cell lung cancer (NSCLC) [133], [134]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.